|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
ChemoCentryx Inc.
| | | Phone: | (650) 210-2900 | Fax: | (650) 210-2910 | Year Established: | 1997 | Ticker: | CCXI | Exchange: | NASDAQ | Main Contact: | Markus J. Cappel, PhD, CBO | | Other Contacts: | William Fairey, Executive VP & COO Rajinder Singh, Ph.D., Senior VP, Research Jan L. Hillson, M.D., Senior VP, Drug Development Susan M. Kanaya, Senior VP, Finance & CFO Petrus (Pirow) Bekker, M.D., Ph.D., CMO Thomas J. Schall, Ph.D., President & CEO
| | Company Description | ChemoCentryx is a clinical-stage biopharmaceutical company primarily focused on developing new medicines for patients with rare renal diseases. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies to treat orphan and rare diseases. Avacopan (CCX168), an inhibitor of the complement 5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). Avacopan was safe, well tolerated and successful in allowing reduction and elimination of high-dose steroids, part of standard of care for AAV patients, while providing effective control of the disease in clinical studies to date. Avacopan is also being developed in patients with atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G). CCX140, an inhibitor of the chemokine receptor known as CCR2, successfully completed a Phase II clinical trial where it was shown to be safe and well tolerated while demonstrating statistically significant improvement in proteinuria in patients with diabetic nephropathy and is currently being developed in a rare kidney disease known as focal segmental glomerulosclerosis (FSGS). Both avacopan and CCX140 are part of a Vifor Pharma-ChemoCentryx Kidney Health Alliance which provides Vifor Pharma with exclusive rights to commercialize avacopan and CCX140 in certain markets outside of the U.S. ChemoCentryx has an immuno-oncology program, which includes a distinct CCR2 inhibitor, CCX872, currently in development for the treatment of advanced non-resectable pancreatic cancer. | |
|
|
|
|
|